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SCN patients are prone to recurrent life-threatening infections.
The main causes of SCN are autosomal dominant mutations in
the ELANE gene that lead to a block in neutrophil differentia-
tion. In this study, we use CRISPR-Cas9 ribonucleoproteins
and adeno-associated virus (AAV)6 as a donor template deliv-
ery system to repair the ELANEL172P mutation in SCN patient-
derived hematopoietic stem and progenitor cells (HSPCs). We
used a single guide RNA (sgRNA) specifically targeting the
mutant allele, and an sgRNA targeting exon 4 of ELANE. Using
the latter sgRNA,34% of the known ELANEmutations can in
principle be repaired. We achieved gene correction efficiencies
of up to 40% (with sgELANE-ex4) and 56% (with sgELANE-
L172P) in the SCN patient-derived HSPCs. Gene repair
restored neutrophil differentiation in vitro and in vivo upon
HSPC transplantation into humanized mice. Mature edited
neutrophils expressed normal elastase levels and behaved
normally in functional assays. Thus, we provide a proof of prin-
ciple for using CRISPR-Cas9 to correct ELANE mutations in
patient-derived HSPCs, which may translate into gene therapy
for SCN.Received 16 March 2020; accepted 5 August 2020;
https://doi.org/10.1016/j.ymthe.2020.08.004.
Correspondence: Klaus Rajewsky, Immune Regulation and Cancer, Max Delbrück
Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-
Strasse 10, 13125 Berlin, Germany.
E-mail: klaus.rajewsky@mdc-berlin.de
Correspondence: Immune Regulation and Cancer, Max Delbrück Center for
Molecular Medicine in the Helmholtz Association, Robert-Rössle-Strasse 10, 13125
Berlin, Germany.
E-mail: vantrung.chu@mdc-berlin.deINTRODUCTION
Severe congenital neutropenia (SCN), a rare inherited monogenic dis-
ease, is diagnosed when the number of mature neutrophils in the pe-
ripheral blood as the absolute neutrophil count (ANC) is below 0.5 
109/L for months or years.1–7 SCN patients tend to develop myelodys-
plastic syndromes (MDSs) or acute myeloid leukemia (AML). This
MDS/AML conversion is often associated with acquired mutations in
the CSF3R gene (encoding the granulocyte colony-stimulating factor
[G-CSF] receptor), and subsequently other leukemia-associated genes
such as RUNX1.8–11 The treatment of children suffering from SCN
with G-CSF reduces the risk of sepsis and infections by increasing the
ANC in the majority of SCN patients. However, SCN patients treated
with G-CSF are at high risk of MDS/AML development, especially in
the case of G-CSF poor responders.4,7,11 For SCN patients who do not
respond to G-CSF or develop MDS/AML, the only available treatmentMolecular
This is an open access article under the CC BY-NC-Noption is allogeneic hematopoietic stem cell transplantation with
frequent adverse effects and high mortality (17%).12,13
Autosomal dominant mutations in the ELANE gene, encoding neutro-
phil elastase (NE), are associated with more severe forms of disease1
and account for 60% of the genetic defects causing SCN.14–16 To
date, more than 200 different ELANE mutations have been identified
in SCN patients. These mutations are predominantly located in exon
4 (34%) and exon 5 (26%), and to a lesser extent in exon 1 (1.6%),
exon 2 (16%), exon 3 (15%), and intron sequences (7%).14,17,18 The
pathophysiological mechanisms by which ELANE mutations cause
SCN are complex and only partially understood.18,19 ELANEmutations
cause an arrest of granulocytic differentiation at the promyelocyte stage
and a strongly impaired production of mature neutrophils. According
to the prevailing view, they can lead to an accumulation of mislocalized
or misfolded NE proteins, which may trigger an unfolded protein
response and apoptosis of granulocytic precursors,20–23 although this
scenario has been challenged.24
Recently, Nasri et al.25 have shown that knock out (KO) of the ELANE
gene in SCN patient-derived hematopoietic stem and progenitor cells
(HSPCs) using CRISPR-Cas9 can rescue neutrophil differentiation.
ELANE KO removed the deleterious effects of misfolded NE and
restored mature neutrophil formation in vitro.25 However, while an
ELANE KO strategy provides a potentially promising treatment for
G-CSF poor responders, it seems to favor the generation, selection,
or outgrowth of edited cells that lack NE expression altogether.25
This causes concern for human patients, since ELANE KO modelsTherapy Vol. 28 No 12 December 2020 ª 2020 The Authors. 2621
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Molecular Therapyin mice have established a non-redundant role for NE in the innate
immune defense against certain microbial infections.26–30 It therefore
seems warranted to explore additional gene-repair approaches that
can fully restore NE and neutrophil function.
In the CRISPR-Cas9 system, a single guide RNA (sgRNA)-directed
Cas9 nuclease introduces specific double-stranded breaks (DSBs) at
the targeted sequence. DSBs are predominantly repaired by the
non-homologous end joining (NHEJ) pathway, causing micro-dele-
tions/insertions (indels). However, if a DNA donor template is
provided, the homology-directed repair (HDR) pathway may be
used to precisely repair DSBs.31–34 Pre-assembled ribonucleoprotein
(RNP) complexes of Cas9 protein and synthetic sgRNA, in combina-
tion with adeno-associated virus (AAV) serotype 6 for donor tem-
plate delivery, have led to high HDR efficiencies in human CD34+
HSPCs.35–38 This approach has been used successfully to repair mu-
tations causing several monogenic blood disorders in patient-derived
HSPCs.39–41 In this study, we describe a CRISPR-Cas9-AAV6-based
ELANE gene repair system that achieves high rates of HDR and re-
stores NE function in the edited neutrophils. We demonstrate the
feasibility of this approach by repairing mutations in exon 4, which
represent 34% of the known autosomal dominant ELANE muta-
tions. Additionally, we selectively repaired an individual patient-
derived missense mutation at amino acid position 172.
RESULTS
Selection of sgRNAs Targeting ELANE and ELANEL172P
A 3-year-old boy was hospitalized and showed typical symptoms of
SCN, including severe neutropenia and infections. A genetic screen
and sequencing analysis identified a heterozygous missense
c.515T>C mutation in the ELANE gene, converting lysine at position
172 into proline (L172P) (Figure 1A). We developed a “universal”
exon 4-based and an L172P-specific CRISPR-Cas9 system to correct
ELANEmutations in exon 4 of the ELANE gene in human HSPCs. Us-
ing CrispRGold,42,43 we designed a universal sgRNA to target a region
of ELANE exon 4 with 60% genome copy (GC) content, termed sgE-
LANE-ex4 hereafter. Since the c.515T>C mutation created a new pro-
tospacer adjacent motif (PAM) signal on the minus strand, we also de-
signed an sgRNA specifically targeting the mutant allele that we term
sgELANE-L172P hereafter (Figure 1B). To assess the editing effi-
ciencies of these sgRNAs, human HSPCs from healthy donors (HD-
HSPCs) or the SCN patient (SCN-HSPCs) were activated and electro-
porated with sgELANE-ex4- or sgELANE-L172P-containing RNPs,
respectively (Figure S1A). At 3 days post-targeting, the sgELANE-
ex4 created indels in up to 90% of target alleles in the HD-HSPCs (Fig-
ures S1B–S1D). As expected, the sgELANE-L172P specifically targeted
the mutant allele with high efficiency (77%), leaving the wild-type
(WT) allele intact (Figures S2A and S2B). Thus, using these sgRNAs,
34% of the known autosomal dominant SCN ELANE mutations
(namely mutations in exon 4) may be targeted with high efficiency.
Off-Target Analysis of sgELANE-ex4 and sgELANE-L172P
To determine the off-target activity of sgELANE-ex4 and sgELANE-
L172P, we used CrispRGold42,43 (https://crisprgold.mdc-berlin.de)2622 Molecular Therapy Vol. 28 No 12 December 2020to predict the off-target sites with the highest risk, based on their
mutation distance to the target site. We selected the top nine and
five off-target sites of sgELANE-ex4 and sgELANE-L172P, respec-
tively, for amplicon deep sequencing (Figure 1C). SCN-HSPCs
were electroporated with or without sgELANE-ex4- or sgELANE-
L172P-containing RNPs, respectively. At 3 days post-editing,
genomic DNA (gDNA) was isolated and off-target amplicons
were amplified by PCR. The PCR amplicons were pooled and
sequenced using MiniSeq. The analysis of these PCR amplicons un-
covered no detectable off-target activity for sgELANE-ex4. In the
case of sgELANE-L172P, a weak but significant increase in indel
events was detected at the top off-target site (OT-11) after treatment
with sgELANE-L172P/RNPs. The frequencies of indel events at OT-
11, however, were at the level of background sequencing error rates
(0.2%) (Figure 1D).Efficient CRISPR-Cas9-Mediated ELANE Correction Systems
Next, to correct ELANE mutations in exon 4 in SCN-HSPCs and to
quantify HDR efficiencies, we generated a DNA donor template
containing ELANE exon 4 including silent mutations, which create
a new SalI restriction site (Figure 1B). We first tested this universal
exon 4-based gene correction approach in HD-HSPCs. To this end,
HD-HSPCs from two donors were electroporated with sgELANE-
ex4 containing RNPs and subsequently infected with AAV6 vectors
carrying the ELANE donor template (AAV6-ELANE), at a multi-
plicity of infection (MOI) of 1  105 GC per cell (Figure 2A). The
combination of sgELANE-ex4/RNPs and AAV6-ELANE donor vec-
tors resulted in an HDR efficiency of 30% in the HD-HSPCs, as
measured by PCR and a SalI-mediated restriction fragment length
polymorphism (RFLP) assay at 3 days post-targeting (Figure 2B).
By Sanger sequencing, we detected approximately 37%, 37%, and
26% of WT, HDR, and indel sequences, respectively (Figure 2C;
Figure S3).
Next, we applied this procedure to the SCN-HSPCs harboring the
ELANEL172Pmutation (Figure 2A). As in the case of the HD-HSPCs,
the SalI-cleaved DNA bands were only detectable in the cells that
received RNPs and the AAV6-ELANE donor vector (Figure 2D).
Quantification of these bands indicated a gene correction efficiency
of approximately 30% and 20% using sgELANE-ex4 and sgELANE-
L172P, respectively (Figure 2E). Indeed, sequencing of the ELANE
locus targeted with sgELANE-ex4/RNPs and AAV6-ELANE donor
vectors confirmed that the ELANE allele was repaired in 40% of
the cases. As sgELANE-ex4 targets both the WT and mutant alleles,
we observed 6% and 8% of indels in the WT and mutant sequences,
respectively (Figure 2F; Figure S4). Of note, in the SCN-HSPCs
receiving sgELANE-L172P/RNPs and AAV6-ELANE donor vectors,
no genetic modifications were detected in the WT allele (Fig-
ure S5A). In contrast, the mutant allele was correctly repaired in
56% of the cases or showed indels in 19% of the cases (Figure 2G;
Figure S5B). Thus, our approach is suitable to efficiently and specif-
ically repair the ELANEL172P mutation and other mutations in exon
4 of the ELANE gene.
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Figure 1. CRISPR-Cas9-Based ELANE Gene Correction and Off-Target Analysis in SCN Patient-Derived CD34+ HSPCs
(A) Schematic of the human ELANE locus, the ELANE cDNA andNE protein including the L172P (c.515T>C)mutation in exon 4 (top), and Sanger sequencing of the dominant
heterozygous ELANEL172Pmutation (bottom). (B) Strategy to correct the ELANEL172Pmutation using CRISPR-Cas9. PAM sequences are indicated in orange. sgELANE-ex4
targets both the wild-type (WT) and the mutant allele. sgELANE-L172P targets specifically the mutant allele. The donor template includes 0.75 kb of 50 and 30 homology arms
(HAs), silent mutations (magenta), and a SalI restriction site. External forward primer (Extern For) and reverse primer (Rev) were used to amplify a 1.5-kb fragment of the
modified ELANE locus. (C) The on-target and highest risk off-target sites of sgELANE-ex4 and sgELANE-L172P, as predicted by CrispRGold (https://crisprgold.mdc-berlin.
de). (D) On-target frequencies were quantified using Sanger sequencing; controls are not shown, as their values are 0. Off-target indel frequencies (on the targeting sequence)
were analyzed using amplicon deep sequencing of SCN patient-derived untreated HSPCs (Ctrl) and HSPCs treated with RNPs (**p < 0.01). Data represent mean ± SD for
three independent experiments. See also Figures S1 and S2.
www.moleculartherapy.orgELANE-Corrected HSPCs Restore Neutrophil Differentiation
In Vitro
To confirm the functionality of the corrected ELANE gene, we differen-
tiated the targeted HSPCs into mature neutrophils in vitro. To this end,
the targetedHSPCs were expandedwith human stem cell factor (hSCF)
and human interleukin-3 (hIL-3) cytokines for 3 days and subsequently
stimulated with human G-CSF (hG-CSF) and human IL-3 for a further
4–10 days (Figure 3A). To answer whether the corrected ELANE gene
restores granulocytic development, we analyzed CD11bCD15+ pro-myelocytes by flow cytometry after 3 days of culture in the presence
of G-CSF. As expected, the ELANE-corrected HSPCs (with either sgE-
LANE-ex4 or sgELANE-L172P) were able to differentiate into
CD11bCD15+ promyelocytes at a level comparable to HD-HSPC-
derived myeloid cultures (50%). In contrast, the SCN-HSPC-derived
progenitor cells showed strongly impaired promyelocyte differentiation
(10%) (Figure 3B). Consistent with previous publications,44,45 we also
observed an increased percentage of CD14+ monocytes/macrophages






Figure 2. Efficiency of ELANE Correction in HD- and SCN Patient-Derived CD34+ HSPCs
(A) Schematic of experiment to assess the efficiency of the ELANE correction in either HD-HSPCs or SCN-HSPCs. (B) Left: SalI-RFLP assays showing the HDR events using
universal exon 4-based ELANE correction (sgELANE-ex4) in HD-HSPCs from two individuals (HD#1 andHD#2). Stars indicate SalI-cleaved fragments. Right: quantification of
three independent duplicate experiments. Data are represented as mean ± SD. (C) Pie chart showing WT, HDR, and indel events of the targeted ELANE locus in HD-HSPCs.
(D) SalI-RFLP assays showing efficiency of universal exon 4-based ELANE- (left) or ELANEL172P-specific (right) correction in SCN-HSPCs. Scars indicate SalI-cleaved bands.
(E) Quantification of the correction efficiency of universal (sgELANE-ex4) and specific (sgELANE-L172P) systems based on three independent experiments. Data are rep-
resented as mean ± SD. (F) Pie chart showing repaired, WT, and mutant (Mut) alleles with or without indel events of the targeted ELANE locus in SCN-HSPCs undergoing
universal exon 4-based ELANE gene correction. (G) Pie chart showing repaired and Mut allele with or without indel events of the targeted ELANE locus in SCN-HSPCs
undergoing the ELANEL172P-specific correction. See also Figures S3–S5.
Molecular Therapy(Figure 3B). Using annexin V staining, we detected apoptotic promye-
locytes. Fluorescence-activated cell sorting (FACS) analyses showed
significantly elevated frequencies of early (annexin V+DAPI) and2624 Molecular Therapy Vol. 28 No 12 December 2020late (annexin V+DAPI+) apoptosis in SCN-HSPC-derived promyelo-
cytes compared with HD-HSPC-derived promyelocytes. ELANE gene







(legend on next page)
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Molecular Therapy(Figure 3C). As a result, while SCN-HSPCs showed impaired neutro-
phil differentiation (< 5%), the ELANE-corrected HSPCs regained
the ability to differentiate into CD11bintCD15+CD16+CD66b+ mature
neutrophils46 with the same efficiency as the HD-HSPCs (40%) (Fig-
ure 3D; Figures S6A–S6C). Notably, the ELANE-repaired neutrophils
expressed NE protein at a level similar to HD-derived neutrophils (Fig-
ure 3E). The mature, edited neutrophils showed the typical
morphology with highly lobulated nuclei (Figure 3F). Thus, ELANE
correction in SCN-HSPCs restored the ability of these cells to differen-
tiate into mature neutrophils in vitro.
ELANE-Corrected Neutrophils Function Normally
To test whether ELANE-repaired mature neutrophils were equivalent
to healthy donor-derived neutrophils, we assessed a variety of func-
tional hallmarks of human neutrophils. First, we measured oxidative
burst as detected by oxidation of dihydrorhodamine 123 (DHR)
from reactive oxygen species (ROS) produced in response to phorbol
myristate acetate (PMA). ELANE-repaired neutrophils (using either
sgELANE-ex4 or sgELANE-L172P) produced ROS levels similar to
HD-HSPC-derived neutrophils (Figures 4A and 4B). Second, we deter-
mined in vitro phagocytic capacity by analyzing the internalization of
opsonized, fluorescent zymosan A particles. HD- and ELANE-repaired
neutrophils displayed similar levels of phagocytosis as indicated by the
median fluorescence intensity and percentage of zymosan+ neutrophils
(Figures 4C and 4D). Third, to assess neutrophil extracellular trap
(NET) formation, HD and ELANE-repaired neutrophils were stimu-
lated for 4 h with PMA, and subsequently fixed and stained to detect
myeloperoxidase (MPO) (present in granules or NETs) andDNA (pre-
sent in nuclei or NETs). ELANE-repaired and HD-derived neutrophils
showed a similar percentage of NETosis (Figures 4E and 4F) and a
similar length of NET chromatin spreading (Figures 4G and 4H).
Finally, we determined intra-phagosomal killing of Gram-negative bac-
teria (E. coli). Both HD- and ELANE-repaired neutrophils exhibited
efficient bacterial killing as indicated by significantly decreased bacte-
rial colony-forming units (CFU) (Figure 4I). These results confirm
that mutant neutrophils upon ELANE gene correction are functionally
indistinguishable from healthy donor-derived neutrophils.
ELANE-Corrected HSPCs Restore Neutrophil Differentiation
In Vivo
To assess whether the ELANE-corrected HSPCs restore neutrophil
differentiation also in vivo, we transplanted such cells (termed
ELANE-repair) into irradiated humanized NOG-EXLmice, which ex-Figure 3. ELANE-Corrected SCN-HSPCs Restore Neutrophil Differentiation In
(A) Experimental scheme of in vitro neutrophil differentiation of ELANE-corrected SCN-H
medium supplemented with human SCF and human IL-3 (phase I). 3 days later, human G
indicated time points. As a positive control, CD34+ HSPCs from a healthy donor were use
macrophages (Mono/Mf) and CD15+ promyelocytes (Promye) in myeloid cultures 10 d
FACS data showing percentages of early (annexin V+DAPI) and late (annexin V+DAPI+) a
independent experiments. (D) FACS data showing the percentages of CD11bintCD15
expression of NE protein in RNPs/AAV6-ELANE-edited SCN- and in HD-HSPC-derived
both anti-human C-terminal and N-terminal NE antibodies; b-actin was detected as loa
HSPCs that did not receive both RNPs and AAV6-ELANE donor vectors. (F) Giemsa sta
groups. Scale bars, 10 mm. See also Figure S6.
2626 Molecular Therapy Vol. 28 No 12 December 2020press human IL-3 and GM-CSF (Figure 5A).47 As a negative control,
mutant SCN-HSPCs were separately transplanted (termed ELANE-
L172P). Prior to transplantation, the percentages of CD34+CD38-
cells among the HSPCs in the ELANE-repair and ELANE-L172P
groups were similar (62%), with an ELANEL172P correction effi-
ciency of about 20% in the ELANE-repair group (Figures S7A and
S7B). At 4 weeks post-reconstitution, human CD45+ cells were de-
tected in the peripheral blood of both the ELANE-L172P and
ELANE-repair groups. However, human CD66b+SSChi neutrophils
were found only in the ELANE-repair group for up to 17 weeks after
transplantation (Figures 5B and 5C). Consistent with this finding, at
20 weeks post-reconstitution, human CD45+ cells were equally de-
tected in the bone marrow and spleen of the transplanted animals
in both experimental groups. As expected, mature neutrophils were
only found in the bone marrow (3.1% ± 1% of total human CD45+
cells) and the spleen (1.4% ± 0.6% of total human CD45+ cells) of
the mice reconstituted with the repaired HSPCs (Figures 6A and
6B). Sanger sequencing of the ELANE gene in mature neutrophils
indeed confirmed that they derived from the repaired HSPCs (Figures
6C and 6D). In contrast, human T, B, natural killer (NK) cells, and
monocytes/macrophages were present at similar frequencies in the
peripheral blood, bone marrow, and spleen of the recipient animals
reconstituted with repaired or non-repaired HSPCs (Figures S8A–
S8E).
To determine whether the ELANE mutation causes an arrest of
neutrophil differentiation at the promyelocyte stage in vivo, we
analyzed the frequencies of human CD33hiCD15+ promyelocytes
and CD33loCD15+ neutrophils in the bone marrow of recipient an-
imals reconstituted with ELANE-L172P and ELANE-repair HSPCs
(Figure 6E). Human promyelocytes and neutrophils were present
at frequencies of 2.0% ± 0.12% and 2.6% ± 0.4%, respectively, in
the bone marrow of mice reconstituted with repaired HSPCs. In
contrast, significantly decreased frequencies of human promyelo-
cytes and neutrophils were detected in the bone marrow of mice
transplanted with non-repaired HSPCs (Figure 6E). Most of the
SCN-HSPC-derived promyelocytes underwent apoptosis, whereas
the corrected ELANE gene rescued the repaired promyelocytes by
significantly decreasing the fraction of apoptotic cells (50% versus
10%) (Figure 6F). Thus, the ELANE-repaired SCN-HSPCs had lost
their propensity to undergo apoptosis at the promyelocyte stage
in vivo and thereby acquired the potential to differentiate into
mature neutrophils in vivo.Vitro
SPCs. Two days after AAV infection, the edited HSPCs were cultured in expansion
-CSF was added (phase II). Myeloid cultures were analyzed by flow cytometry at the
d (HD-HSPCs). (B) Left: FACS data showing the percentages of CD14+monocytes/
ays after targeting. Right: quantification of two independent experiments. (C) Left:
poptotic cells amongCD15+ promyelocytes gated on (B). Right: quantification of two
+ mature neutrophils at the indicated time points. (E) Western blot data showing
myeloid cultures at day 18 of neutrophil differentiation. NE protein was detected with
ding control. NE protein was not detectable in myeloid cultures derived from SCN-










Figure 4. ELANE Correction Restores Neutrophil Functions
ELANE-repaired neutrophils were analyzed for various neutrophil functions and compared to neutrophils from healthy donors (HD neutrophils). (A) FACS data showing the
percentages of neutrophils producing reactive oxygen species (ROS) after stimulation with phorbol myristate acetate (PMA) and staining with dihydrorhodamine 123 (DHR).
(B) Quantification of two independent experiments. Data are represented as mean ± SD. (C) Histograms showing the percentages and fluorescence intensities of neutrophils
(legend continued on next page)
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Figure 5. Human Neutrophils in Peripheral Blood of Recipient Mice Reconstituted with ELANE-Corrected HSPCs
(A) Experimental scheme of ELANEL172P correction in SCN-HSPCs and transplantation of these cells into humanized NOG-EXL mice. Human cells were monitored in the
peripheral blood of transplanted mice every 4 weeks. (B) FACS data showing the percentage of human CD45+ cells and standard saline citrate (SSC)hiCD66b+ neutrophils in
the peripheral blood of recipient animals reconstituted with ELANE-repaired (orange) or non-repaired (ELANE-L172P, black) HSPCs at 8 weeks post-transplantation. (C)
Percentages of human CD45+ cells (left) and human SSChiCD66b+ neutrophils (right) in the peripheral blood of reconstituted mice at the indicated time points after
transplantation. Data represent mean ± SD for three mice. See also Figures S7 and S8.
Molecular TherapyDISCUSSION
Approximately 60% of SCN patients harbor autosomal dominant
monoallelic ELANE mutations that cause an arrest in neutrophil
development, resulting in a profound deficiency of mature neutro-
phils.20,22 As a result, SCN patients are prone to recurrent life-threat-
ening infections. Although administration of supraphysiological con-
centrations of G-CSF can override the developmental defect by
compensatory mechanisms19 and helps80% of SCN patients, it fails
to correct the immune defense function of the mutated neutrophils48
and increases the risk of MDS/AML through mutations in the CSF3R
gene (encoding the G-CSF receptor), especially in G-CSF poor re-
sponders (20%).4,7,11 Thus, nuclease-mediated gene correction in
autologous HSPCs with subsequent transplantation represents an
attractive alternative, in particular for patients who respond poorly
to G-CSF.
In principle, neutrophil differentiation in SCN patients can be rescued
by precise gene correction of ELANE mutations in SCN-derived
HSPCs (as shown here) or by KO of the mutant ELANE allele.25
Neutrophil counts in humans carrying a genetic deletion of oneafter phagosomal uptake of antibody-opsonized Alexa Fluor 488-conjugated zymosa
images of the HD- and ELANE-repaired neutrophils stimulated with solvent (DMSO) or
NETosis (released NETs as shown in E); each dot represents one captured image from
ELANE-repaired neutrophils stimulated with DMSO or PMA and stained with anti-myelo
chromatin spreading as shown in (G); each dot represents one captured image from six s
quantification of colony-forming units (CFU) after 0 and 60 min incubation at 37C in the
represent mean ± SD of two technical replicates.
2628 Molecular Therapy Vol. 28 No 12 December 2020ELANE allele are normal,49 and NE KO mice produce normal
numbers of mature neutrophils with the ability to migrate, phagocy-
tose, and form NETs in a model of deep vein thrombosis.26,27,50
Accordingly, a recent report indicated that CRISPR-Cas9-mediated
ELANE KO in SCN patient-derived HSPCs can rescue neutrophil dif-
ferentiation in vitro.25 However, this study did not address the allelic
status of the edited HSPCs. The KO strategy produced neutrophils
that were elastase-negative,25 suggesting that selectively removing
mutated alleles while preserving intact WT alleles in the same cell
may be difficult to achieve. Indeed, complete KO of ELANE in human
neutrophils may prove problematic with respect to certain infections,
given that NE has important and non-redundant roles in the intracel-
lular and extracellular defense against bacterial and fungal pathogens
in mice26–30 and humans.28,51,52
To more precisely correct autosomal dominant ELANE mutations in
SCN patient-derived HSPCs and thereby cure SCN, we developed a
CRISPR-Cas9-AAV6-based gene repair approach. We achieved effi-
cient ELANE gene correction (40%) in SCN patient-derived HSPCs
that maintained engraftment capacity upon transplantation inton particles. (D) Quantification of two independent experiments. (E) Representative
PMA and stained for DNA with DAPI (blue). Scale bars, 10 mm. (F) Quantification of
six slides in two independent experiments. (G) Fluorescent images of the HD- and
peroxidase (MPO; red) and DAPI (blue). Scale bars, 10 mm. (H) Quantification of NET
lides in two independent experiments. (I) Intra-phagosomal bacterial killing of E. coli:
absence (Crtl) or presence of 2  105 the HD- or ELANE-repaired neutrophils. Data
www.moleculartherapy.orghumanized mice. Furthermore, ELANE correction fully restored
neutrophil differentiation, both in vitro and in vivo. Mature, repaired
neutrophils showed normal NE expression and neutrophil functions
such as ROS generation, phagocytosis, anti-bacterial activity, and
NET formation.
We demonstrated the feasibility of our approach with an efficient
whole-exon-based ELANE gene correction strategy as well as a gene
correction strategy for single mutations that can be tailored to indi-
vidual patients. In case of the whole exon-sgRNA-based strategy,
which targets exon 4 and covers34% of the known autosomal domi-
nant ELANEmutations, we achieved gene correction efficiencies of up
to 40%. One allele may be lost by KO, but the repaired allele is suffi-
cient to allow mature neutrophil differentiation. In case of the ELA-
NEL172P-specific correction, 56% of HSPCs can be repaired without
editing the WT allele.
Regarding safety, off-target mutation frequencies at the top nine off-
target sites of sgELANE-ex4 were below detection levels based on am-
plicon deep sequencing. In the case of sgELANE-L172P, indels were
detected at the top off-target site at very low frequencies (<0.2%)
and intronic. Consistent with previous publications, our study sup-
ports the notion that off-target activity can be largely avoided by
the use of specific sgRNAs.53
Our experiments in NOG-EXL humanized mice indicate that the
transplanted ELANE-corrected HSPCs maintain engraftment and
lineage differentiation capacity.47 In the humanized mice engrafted
with the repaired HSPCs, human B cells, NK cells, neutrophils, and
myeloid cells were observed up to 20 weeks after transplantation,
while human T cells were hardly detectable. Apart from the low
T cell numbers, no abnormalities of hematopoietic development
were seen in the transplanted animals until the end of the experi-
ments. Thus, given its efficiency, safety, and functionality, ELANE




NOG-EXL mice, expressing human GM-CSF and IL-3 cytokines,
were purchased from Taconic Biosciences (New York, NY, USA).
All animal experiments were approved by the Institutional Animal
Care and Use Committee (Berlin LaGeSo) and performed by EPO
(Berlin, Germany).
Human HSPC Isolation and Culture
Human CD34+ HSPCs were isolated frommobilized peripheral blood
of healthy donors or bone marrow of the SCN patient using Ficoll-Pa-
que Plus (GE Healthcare, Chicago, IL, USA) and a human CD34 mi-
crobead kit according to the manufacturer’s protocol (Miltenyi Bio-
tec, Bergisch Gladbach, Germany). 2  105 CD34+ HSPCs were
cultured in 1 mL of serum-free StemSpan serum-free expansion me-
dium (SFEM) II (STEMCELL Technologies, Cologne, Germany) sup-
plied with human SCF (100 ng/mL), human thyroperoxidase (TPO)(100 ng/mL), human fms-related tyrosine kinase 3 ligand (FLT3L)
(100 ng/mL), human IL-6 (100 ng/mL) (PeproTech, Hamburg, Ger-
many), UM171 (35 nM, STEMCELL Technologies, Cologne, Ger-
many), and SR1 (0.75 mM, STEMCELL Technologies, Cologne,
Germany).
AAV-ELANE Repair Template Cloning and Production
To generate the pAAV-ELANE donor vector, a 1.6-kb ELANE gene
fragment containing exon 4 and the left and right homology arms
were amplified from human genomic DNA and cloned into XhoI/
KpnI sites of the pTV vector. Silent mutations and the SalI recogni-
tion site were added by overlapping PCR. The NotI-flanked ELANE
fragment was cloned into the pAAV-DJ backbone vector (Cell Bio-
labs, San Diego, CA, USA). To produce recombinant AAV6
(rAAV6) viruses, HEK293T cells were co-transfected with pAAV-
ELANE, pAAV6-Rep/Cap, and pAAV-Helper plasmids using the pol-
yethylenimine (PEI) transfection protocol. 12 h later, the mediumwas
replaced by DMEM+/+ supplemented with 10% fetal calf serum (FCS),
25 mMHEPES (Gibco, Carlsbad, CA, USA), and 10 mg/mL gentamy-
cin (Lonza, Basel, Switzerland). Three days later, the cell pellet was
collected and lysed by three cycles of thaw-freeze in a dry ice/ethanol
bath (10 min per cycle). Then, the cell lysate was cleared by spinning
at 3,500 rpm for 15 min. The cleared supernatant was transferred into
new Falcon tubes and treated with DNA endonuclease Benzonase
(Millipore, Darmstadt, Germany) for 1 h at 37C. The cell lysate
was spun down and the supernatant was loaded into iodixanol
gradient tubes (Beckman, Krefeld, Germany) and fractionated by ul-
tra-centrifugation at 58,000 rpm for 130 min at 18C, using a type
70Ti rotor (Beckman, Krefeld, Germany). The 40% iodixanol layer
was collected using an 18G needle and syringe. The supernatant
was filtered through a 0.2-mm polyethersulfone (PES) filter and dia-
lyzed overnight with PBS at 4C in dialysis cassettes (Thermo Scien-
tific, Waltham, MA, USA). Finally, the rAAV6 supernatant was
concentrated using Amicon Ultra-15 centrifugal filter units (Milli-
pore, Darmstadt, Germany). The concentration of rAAV6 viruses
was measured by real-time PCR using TaqMan probes specific for
the AAV inverted terminal repeat (ITR) sequence (Thermo Scientific,
Waltham, MA, USA).
sgRNA, Cas9 Protein, and Antibodies
To design a universal sgRNA targeting ELANE exon 4, the coding
sequence of ELANE exon 4 was mapped to the human genome
(Homo sapiens, hg38) using the latest version of CrispRGold
(https://crisprgold.mdc-berlin.de) to identify potential off-target sites,
GC content, and folding energy between the targeting sequence and
the scaffold RNA. sgRNA with the lowest off-target risk score >11,
melting temperature (Tm) %60C, and a scaffold-folding energy %
20 kcal/mol was selected.42,43 Synthetic sgELANE-ex4 and sgE-
LANE-L172P were purchased from Synthego (Menlo Park, CA,
USA). Cas9 protein was purchased from Integrated DNA Technolo-
gies (Leuven, Belgium). The following antibodies were purchased
from BioLegend (Koblenz, Germany): anti-human CD45-Brilliant
Violet (BV)605, anti-mouse CD45-phycoerythrin (PE)/Cy7, anti-hu-






Figure 6. ELANE-Corrected HSPCs Restore Neutrophil Differentiation In Vivo
(A) FACS data showing the frequencies of human CD45+ cells (top) or CD33+CD15+CD66b+ mature neutrophils (Neu) (bottom) in the bone marrow (left) or spleen (right) of
recipients at 20 weeks post-transplantation with non-repaired (ELANE-L172P) or repaired (ELANE-repair) HSPCs. (B) Absolute numbers of humanCD45+ cells or neutrophils
in the bonemarrow (left) or spleen (right) of transplanted animals 20weeks after reconstitution. Data are represented asmean ± SD for threemice. *p < 0.05 (two-tailedMann-
Whitney test). (C) Representative sequences of the ELANE WT, Mut, and repaired (Re) alleles in human mature neutrophils isolated from recipients 20 weeks after trans-
plantation. The WT T nucleotide is indicated in red, the Mut C nucleotide in is indicated in blue, and silent mutations are indicated in magenta. (D) Pie chart summarizing the
frequencies of the ELANEWT and repaired alleles in mature neutrophils. (E) Left: FACS data showing percentages of human CD33hiCD15+ Promye and CD33loCD15+ Neu in
human CD45+ cells in the bone marrow of recipients 20 weeks after transplantation. Right: quantification for three mice; data are represented as mean ± SD. (F) Left:
histograms showing annexin V+ apoptotic cells in humanCD33hiCD15+ promyelocytes from recipients 20weeks after reconstitution. Right: quantification for three mice; data
are represented as mean ± SD. See also Figures S7 and S8.
Molecular Therapyallophycocyanin (APC), anti-human CD15-APC, anti-human
CD11b-PE/Cy7, anti-human CD16-BV711, anti-human CD66b-
FITC, anti-human CD33-BV785, anti-human CD56-BV421, anti-hu-
man CD34-APC, anti-human CD38-PE/Cy7.2630 Molecular Therapy Vol. 28 No 12 December 2020RNP Electroporation and AAV6 Infection
To generate the RNP complexes, Cas9 proteins (50 pmol) were mixed
with synthetic sgRNAs (100 pmol) at a 1:2molarity ratio and incubated
at 25C for 10min.HumanCD34+HSPCswere cultured for 3 days and
www.moleculartherapy.orgthen washed once with PBS. 2 105 CD34+ cells were suspended into
20 mL of P3 electroporation buffer (Lonza, Basel, Switzerland) contain-
ing gRNA-Cas9 RNPs. After electroporation using the DZ-100 pro-
gram (4D, Lonza, Basel, Switzerland), the cells were transferred to
pre-warmed SFEM II medium supplied with cytokines and placed
into an incubator at 37C and 5% CO2. 30 min later, the rAAV6 par-
ticles were added to electroporated cells at a anMOI of 1 105 GC/cell.
The medium was changed the next day. At 3 days post-targeting, the
dead cells were removed by using a dead cell removal kit according
to the manufacturer’s protocol (Miltenyi Biotec, Bergisch Gladbach,
Germany). The living CD34+ HSPCs were analyzed or harvested for
genomic DNA extraction for further analysis.
PCR, T7EI, and RFLP Assays
Genomic DNA from the targeted human CD34+ HSPCs was ex-
tracted using the QuickExtract DNA extraction kit (Epicenter, Hes-
sisch Oldendorf, Germany) following the manufacturer’s protocol.
A T7EI assay was performed as described previously.34 For the
RFLP assay, the targeted fragments were amplified using the Thermo-
coccus kodakarensis (KOD) hot start DNA polymerase (Millipore,
Darmstadt, Germany) with gene-specific primers (Table S1). PCR
products were purified using AMPure XP beads (Beckman Coulter,
Krefeld, Germany) and digested with SalI restriction enzyme for
1 h at 37C. Cleaved DNA fragments were separated on 1.2% agarose
gel, and the DNA concentration of each band was quantified using
ImageJ software (NIH, Bethesda, MD, USA). Percentages of indels
and HDR were calculated as described.31
DNA Sequencing
PCR products were cloned into the pJET plasmids (Thermo Scientific,
Waltham, MA, USA) following the manufacturer’s protocol. Plas-
mids were isolated using the NucleoSpin plasmid (Macherey-Nagel,
Dueren, Germany). Plasmids were sequenced using gene-specific
primers (Table S1) by the the Sanger method (LGC Genomics, Berlin,
Germany).
Analysis of Off-Targets by PCR Amplicon Deep Sequencing
To perform amplicon deep sequencing for off-target analysis, nine and
five of the highest risk off-target sites for sgELANE-ex4 and sgELANE-
L172P were selected using CrisprGold, respectively. All off-target sites
analyzed were first amplified from genomic DNA by PCR using KAPA
HiFi HotStart Mix (Kapa Biosystems, Basel, Switzerland) with gene-
specific primers, including overhang adaptor sequences that are com-
parable to IIlumina Nextera XT index adapters (Table S1), and the
following PCR conditions: 95C for 3 min, 20 cycles (98C for 20 s,
60C for 15 s, 72C for 20 s), and 72C for 1 min. PCR products
were purified using AMPure XP beads, quantified using a Qubit dou-
ble-stranded DNA (dsDNA) high-sensitivity (HS) assay kit (Invitro-
gen,Waltham,MA,USA) and normalized to 1 ng/mL. Formultiplexing
sequencing libraries these PCR products were indexed through a sec-
ond PCR with a Nextera XT DNA library preparation kit v2 set A (Il-
lumina, Berlin, Germany) using KAPA HiFi HotStart mix and
following PCR conditions: 95C for 3 min, 8 cycles (98C for 20 s,
60C for 15 s, 72C for 20 s), and 72C for 1 min. Indexed PCR prod-ucts were cleaned using AMPure XP beads, quantified using a Qubit
dsDNA HS assay kit, normalized to 10 ng/mL, and pooled. The ampli-
con libraries were loaded onto an Illumina MiniSeq for deep
sequencing. The deep sequencing reads were filtered for quality and
mapped to the amplicons using an in-house-developed tool. The indel
events on the off-target site (targeting sequence) were quantified and
normalized to the number of reads covering the locus.
CD34+ Cell Transplantation
At 3 days post-targeting, corrected CD34+ HSPCs were collected and
washed twice with PBS. Dead cells were removed using a dead cell
removal kit (Miltenyi Biotec, Bergisch Gladbach, Germany). The
living CD34+ cells were washed once with PBS. 2  105 CD34+ cells
were intravenously injected into irradiated (1 Gy), 4-week-old NOG-
EXLmice. 4, 8, 12, or 17 weeks after reconstitution, the human cells in
the peripheral blood of the transplanted mice were analyzed by flow
cytometry. Human cells were analyzed in the bone marrow and
spleen of the recipient animals after 20 weeks of reconstitution.
In Vitro Neutrophil Differentiation
HD-HSPCs, SCN-HSPCs, or corrected SCN-HSPCs were cultured in
Iscove’s modified Dulbecco’s medium (IMDM) (Gibco, Carlsbad,
CA, USA) supplemented with 10% FBS, 2 mM L-glutamine, human
SCF (100 ng/mL), and human IL-3 (100 ng/mL) for 3 days. At day
4, G-CSF (20 ng/mL) was added to the previous medium. Cells
were cultured for another 10 days. Mature neutrophils were deter-
mined by FACS as CD11bintCD15+CD16+CD66b+ cells and Giemsa
staining to observe the lobulated nuclear morphology.
Analysis of ROS Production Using DHR Flow Cytometric Assay
To measure ROS production, 5x104 the ELANE-corrected and HD-
derived neutrophils were first stained with surface makers and subse-
quently suspended in 200 mL of Hanks’ balanced salt solution (HBSS)
(without CaCl2 and MgCl2) containing 100 mM DHR (Invitrogen,
Waltham, MA, USA) and 500 U of catalase (Sigma, Munich, Ger-
many) and incubated at 37C for 5 min. PMA (Sigma, Munich, Ger-
many) was added to 1 mM final concentration and followed by incu-
bation for 15 min. The cells were immediately analyzed by flow
cytometry.
Analysis of Phagocytic Capacity Using Zymosan Uptake Assay
To measure phagocytic capacity, 1  105 differentiated neutrophils
were resuspended in 100 mL of HBSS (without CaCl2 andMgCl2) con-
taining 1 106 human serum-opsonized Alexa Fluor 488-conjugated
zymosan A BioParticles (Invitrogen, Waltham, MA, USA) and were
incubated at 37C for 30 min. Cells were then washed three times
with PBS and resuspended in 1 mL of lyticase (100 U/mL) (Sigma,
Munich, Germany) and were incubated at 37C for 20 min to remove
extracellular zymosan. To this end, these cells were washed with PBS,
stained with surface markers, and analyzed by flow cytometry.
NET Formation
To quantify NETosis and measure the length of NET chromatin
spreading, 2  104 ELANE-corrected and HD-derived neutrophilsMolecular Therapy Vol. 28 No 12 December 2020 2631
Molecular Therapywere seeded in a poly-L-lysine-coated chamber slide at 37C for
30 min. These cells were then treated with 100 nM PMA for 4 h at
37C. PMA-treated neutrophils were fixed by using 4% paraformal-
dehyde (Sigma, Munich, Germany) for 15 min at 37C followed by
permeabilizing with PBS/0.25% Triton X-100 for 15 min at room
temperature (RT). The slides were stained with primary antibody rab-
bit anti-human MPO (1:400, Dako/Agilent Technologies, Wald-
bronn, Germany) at RT for 1 h. The slides were washed three times
with PBS/0.05% Tween 20 and developed with secondary antibody
goat anti-rabbit immunoglobulin G (IgG) Alexa Fluor 546 (1:600, In-
vitrogen, Waltham, MA, USA) for 1 h at RT. The slides were washed
and mounted using Fluoromount aqueous mounting medium
(Sigma, Munich, Germany). Nuclei and DNA were counterstained
with DAPI. The stained neutrophils were captured and analyzed for
NETosis and NET chromatin spreading using a Keyence BZ-X800
microscope system.
Anti-Bacterial Activity of Neutrophils
Two strains of E. coli ATCC 8739 (ATCC, Manassas, VA, USA) and
DH10B (Thermo Scientific, Waltham, MA, USA) were used for
neutrophil-mediated bacterial killing assays. To this end, 2  105
differentiated neutrophils were mixed with 1  106 bacterial cells in
a final volume of 200 mL of HBSS (with CaCl2 and MgCl2). Human
serum (Sigma, Munich, Germany) was added to give a 1% final con-
centration for opsonization. At start (0) and 60 min of incubation,
10 mL of reaction mixture was removed and added to 1 mL of endo-
toxin-free distilled water, adjusted to pH 11, vortexed vigorously for
5 min, and diluted in PBS and 100-mL samples were plated on Lu-
ria-Bertani (LB) agar for duplicate viable counts after 18 h at 37C.
The numbers of CFU were determined at 0 and 60 min of incubation
by plating serial 10-fold dilutions on LB agar.
FACS Analysis
To analyze human cells in the peripheral blood of the transplanted
mice, red blood cells were lysed twice with red blood cell buffer. Sin-
gle-cell suspensions were prepared from bone marrow and spleen of
the recipient animals. These cells were blocked with FcgR antibodies
(BioLegend, Koblenz, Germany) for 10 min at 4C. Subsequently,
these cells were stained with fluorescent-conjugated antibodies for
15 min at 4C. The cells were finally washed with FACS buffer
(PBS/1% BSA) and analyzed by BD LSRFortessa. The data were
analyzed using FlowJo. In vitro- and in vivo-differentiated human
promyelocytes were analyzed for apoptosis using an annexin V stain-
ing kit according to the manufacturer’s instructions (BD Pharmingen,
Heidelberg, Germany). By gating on CD11bCD15+ population
in vitro, early and late apoptosis levels were determined as annexin
V DAPI and annexin V+DAPI+, respectively.
Western Blotting
To detect NE protein in the differentiated neutrophils, SCN, edited
(RNPs only or RNPs/AAV6-ELANE), and HD-HSPC-derived
myeloid cells were harvested and lysed at the end of in vitro neutro-
phil differentiation. The lysates were then run on SDS-PAGE gel and
transferred into a polyvinylidene fluoride (PVDF) membrane. The2632 Molecular Therapy Vol. 28 No 12 December 2020NE protein was developed with anti-human C-terminal (R&D Sys-
tems, Minneapolis, MN, USA) and anti-human N-terminal (Sigma,
Munich, Germany) NE antibodies; b-actin (Sigma, Munich, Ger-
many) was used for loading controls.
Statistical Analysis
Statistical tests were performed using Prism 7.0 (GraphPad, San
Diego, CA, USA) using a two-tailed Mann-Whitney test or two-
way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001).
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